{"id":"W2757427979","doi":"10.1200/jco.2017.35.15_suppl.9504","title":"Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Discontinuation; Medicine; Pembrolizumab; Population; Ipilimumab; Internal medicine; Family medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001843015,0.0002869091,0.002145468,0.0002051569,0.0001394492,0.00003976083,0.0005448859,0.0002388176,0.00008606073],"category_scores_gemma":[0.0007461807,0.0001466336,0.0004390015,0.0001262687,0.0003701829,0.000233699,0.00005250654,0.0007968454,0.000005941812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005264351,"about_ca_system_score_gemma":0.0007760004,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002291124,"about_ca_topic_score_gemma":0.002118781,"domain_scores_codex":[0.9956744,0.0007871787,0.002347434,0.0003093457,0.0005225948,0.0003590441],"domain_scores_gemma":[0.9950932,0.001411456,0.002407044,0.000673369,0.0002471977,0.0001677799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1029802,0.0175037,0.704962,0.000009398764,0.0006040829,0.001144147,0.000815105,0.000002114085,0.00001440925,0.000001769579,0.00006057078,0.1719024],"study_design_scores_gemma":[0.2084562,0.08026011,0.7094069,0.0001195624,0.0002736875,0.00006575194,0.0004599136,0.00001261478,0.000005310213,0.000009991198,0.000818171,0.0001117312],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944947,0.0001686241,0.000007690314,0.002543129,0.0006601411,0.00122939,0.00001105736,0.000006242665,0.0008790015],"genre_scores_gemma":[0.9981817,0.0002678587,0.00009145384,0.001039783,0.0001924892,0.0000264768,0.00000733142,0.00002305048,0.0001698409],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1717907,"threshold_uncertainty_score":0.5979545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1240299827595494,"score_gpt":0.4848306160490523,"score_spread":0.3608006332895029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}